FOXC1 (NM_001453) Human Tagged ORF Clone Lentiviral Particle
CAT#: RC215629L3V
- LentiORF®
-
Lenti ORF particles, FOXC1 (Myc-DDK tagged) - Human forkhead box C1 (FOXC1), 200ul, >10^7 TU/mL
Need custom lentivirus service?
Get a free quote
CNY 10,070.00
货期*
详询
规格
Product images
![](https://cdn.origene.com/img/defaults-img.jpg)
经常一起买 (3)
Specifications
Product Data | |
Product Name | FOXC1 (NM_001453) Human Tagged ORF Clone Lentiviral Particle |
Synonyms | ARA; ASGD3; FKHL7; FREAC-3; FREAC3; IGDA; IHG1; IRID1; RIEG3 |
Vector | pLenti-C-Myc-DDK-P2A-Puro |
ACCN | NM_001453 |
ORF Size | 1659 bp |
Sequence Data |
The ORF insert of this clone is exactly the same as(RC215629).
|
OTI Disclaimer | The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info |
OTI Annotation | This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene. |
Reference Data | |
RefSeq | NM_001453.2 |
RefSeq Size | 3452 bp |
RefSeq ORF | 1662 bp |
Locus ID | 2296 |
Protein Families | Druggable Genome, Transcription Factors |
MW | 56.6 kDa |
Gene Summary | This gene belongs to the forkhead family of transcription factors which is characterized by a distinct DNA-binding forkhead domain. The specific function of this gene has not yet been determined; however, it has been shown to play a role in the regulation of embryonic and ocular development. Mutations in this gene cause various glaucoma phenotypes including primary congenital glaucoma, autosomal dominant iridogoniodysgenesis anomaly, and Axenfeld-Rieger anomaly. [provided by RefSeq, Jul 2008] |
Documents
Product Manuals |
FAQs |
SDS |
Resources
You may also need
Customer
Reviews
Loading...